登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Claudin-18.2 >CL2-H5587

Human / Cynomolgus Claudin-18.2 Protein, His,Twin-Strep Tag (Detergent)

分子别名(Synonym)

Claudin-18.2,CLDN18,Claudin-18

表达区间及表达系统(Source)

Human / Cynomolgus Claudin-18.2, His,Twin-Strep Tag (CL2-H5587) is expressed from Baculovirus-Insect cells. It contains AA Met 1 - Ala 200 (Accession # P56856-2). In the region AA Met 1 - Ala 200, the AA sequence of Human and Cynomolgus Claudin-18.2 are homologus.

Predicted N-terminus: His

Request for sequence

蛋白结构(Molecular Characterization)

Claudin-18.2 Structure

This protein carries a polyhistidine tag at the N-terminus and a twin strep tag at the C-terminus.

The protein has a calculated MW of 26.3 kDa.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>80% as determined by SDS-PAGE.

制剂(Formulation)

This product is not suitable for cell based experiments due to cytotoxicity of DDM.
DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumastance should you remove DDM and CHS.
DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution.

Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped with dry ice, please inquire the shipping cost.

存储(Storage)

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. The product MUST be stored at -70°C or lower upon receipt;
  2. -70°C for 6 months under sterile conditions.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
*The DDM/CHS buffer (Cat. No. DC-11) is sold separately and not included in protein, you can follow this link for product information.
 

活性(Bioactivity)-ELISA

Claudin-18.2 ELISA

Immobilized Human / Cynomolgus Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5587) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 (Cat. No. CL2-M34) with a linear range of 0.1-2 ng/mL (QC tested).

Protocol

Claudin-18.2 ELISA

​Immobilized Human / Cynomolgus Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5587) and Human Claudin-18.1, His,Twin-Strep Tag ( Cat. No. CL1-H5588) at 5 μg/mL (100 μL/well) respectively, the Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 can bind the Human / Cynomolgus Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5587) with a linear range of 0.2-16 ng/mL, but can not bind the Human Claudin-18.1, His,Twin-Strep Tag (Cat. No. CL1-H5588) (Routinely tested).

Protocol

 

活性(Bioactivity)-SPR

Claudin-18.2 SPR

Anti-Claudin-18.2 mAb captured on CM5 chip via anti-Human IgG (Fc) antibody can bind Human / Cynomolgus Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5587) with an affinity constant of 6.72 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

Claudin-18.2 BLI

Loaded Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 on AHC Biosensor, can bind Human / Cynomolgus Claudin-18.2, His,Twin-Strep Tag (Cat. No. CL2-H5587) with an affinity constant of 3.03 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 
评论(1)
 
ACRO质量管理体系
 
 

背景(Background)

Claudins (CLDNs) are a family of proteins that form tight junctions and maintain the polarity of epithelial and endothelial cells. CLDN18 is specifically expressed in the stomach and lung. Of the two CLDN18 isoform transcripts produced by alternative splicing, CLDN18.2 is a highly selective gastric lineage marker that determines the gastric phenotype in a neoplastic condition, whereas CLDN18.1 is lung specific. CLDN18.2 is a highly selective gastric lineage antigen expressed exclusively on short-lived differentiated gastric epithelial cells where it has only limited accessibility to antibody drugs.14,15 CLDN18.2 is maintained during the course of malignant transformation and thus frequently displayed on the surface of human gastric cancer cells.

 

前沿进展

Advances and challenges in gastric cancer testing: the role of biomarkers
Sun, Puspanathan, Lim et al
Cancer Biol Med (2025)
Abstract: Advances in the identification of molecular biomarkers and the development of targeted therapies have enhanced the prognosis of patients with advanced gastric cancer. Several established biomarkers have been widely integrated into routine clinical diagnostics of gastric cancer to guide personalized treatment. Human epidermal growth factor receptor 2 (HER2) was the first molecular biomarker to be used in gastric cancer with trastuzumab being the first approved targeted therapy for HER2-positive gastric cancer. Programmed death-ligand 1 positivity and microsatellite instability can guide the use of immunotherapies, such as pembrolizumab and nivolumab. More recently, zolbetuximab has been approved for patients with claudin 18.2-positive diseases in some countries. More targeted therapies, including savolitinib for MET-positive patients, are currently under clinical investigation. However, the clinical application of these diagnostic approaches could be hampered by many existing challenges, including invasive and costly sampling methods, variability in immunohistochemistry interpretation, high costs and long turnaround times for next-generation sequencing, the absence of standardized and clinically validated diagnostic cut-off values for some biomarkers, and tumor heterogeneity. Novel testing and analysis techniques, such as artificial intelligence-assisted image analysis and multiplex immunohistochemistry, and emerging therapeutic strategies, including combination therapies that integrate immune checkpoint inhibitors with targeted therapies, offer potential solutions to some of these challenges. This article reviews recent progress in gastric cancer testing, outlines current challenges, and explores future directions for biomarker testing and targeted therapy for gastric cancer.Copyright © 2025 The Authors.
Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy
Arseneau, Kempster, Bekkers et al
Transl Oncol (2025) 55, 102362
Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal, with a five-year survival rate below 15 %. Claudin 18.2 (CLDN18.2) has emerged as a novel potential therapeutic target in PDAC. Zolbetuximab, a monoclonal antibody targeting CLDN18.2, has demonstrated therapeutic benefit in gastric cancers and is now in phase 2 clinical trials for PDAC. Trial eligibility for zolbetuximab requires tumor membranous immunohistochemical staining with the pan-claudin 18 companion diagnostic antibody clone 43-14A. However, the expression of CLDN18 detected using this clone has only been evaluated in 62 patients from a single retrospective study. Herein, we report immunohistochemical staining using 43-14A on surgically resected PDAC samples (n = 120). Samples were stained following the protocol used in clinical trials, using the 43-14A VENTANA antibody in a prediluted kit, and according to the manufacturer's recommended protocol. Positive cases were defined as ≥ 75 % of tumor cells exhibiting membranous staining with an intensity of ≥ 2+. Out of 120 PDAC cases, 39 (32.5 %) stained positive for CLDN18 with 43-14A. A significant association was observed between lower tumor grade and higher 43-14A staining (p < 0.05). CLDN18-positive cases demonstrated significantly improved survival at the cohort's median overall survival (23 months, p < 0.05), suggesting that claudin expression could serve as a both a diagnostic and prognostic marker. Our findings indicate that 32.5 % of PDAC tumors in this cohort are positive for CLDN18, suggesting that a significant proportion of patients with PDAC could benefit from zolbetuximab and other CLDN18.2 targeted immunotherapies if pancreatic cancer therapeutic trials prove successful.Copyright © 2025. Published by Elsevier Inc.
Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
Alsina Maqueda, Teijo Quintáns, Cuatrecasas et al
Clin Transl Oncol (2025)
Abstract: Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care.© 2025. The Author(s).
Evaluating the pharmacokinetics of zolbetuximab in gastric adenocarcinoma
Rogers, Leung, Ajani
Expert Opin Drug Metab Toxicol (2025)
Abstract: Gastric adenocarcinoma (GAC) represents a heterogeneous disease making treatment advancements difficult. Recently, claudin 18.2 (CLDN18.2) has emerged as an exciting new target in GAC. Zolbetuximab, an anti-CLDN18.2 monoclonal antibody, has now been FDA approved.Phase 1, 2, and 3 zolbetuximab trials have been completed in GAC. Phase 3 trials evaluating zolbetuximab in combination with front-line fluoropyrimidine plus platinum therapy improved survival endpoints compared to placebo plus chemotherapy in those with high CLDN18.2 positivity (>75% of tumor cells). This led to zolbetuximab's FDA approval in this population. Here, we review aspects of zolbetuximab's pharmacology known at this time.Zolbetuximab is one of many agents targeting CLDN18.2 under development. Zolbetuximab in combination with chemotherapy has a slight impact on high CLDN18.2 expressed GAC to chemotherapy alone. Examining how to improve upon outcomes will be of benefit. Additionally, there are GAC subsets who may have benefit from zolbetuximab but need more close examination such as those with moderate CLDN18.2 expressed tumors, low CLDN18.2 expressed tumors, and CLD18-ARHGAP fusion patients.
Showing 1-4 of 170 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Claudin-18.2靶点信息
英文全称:Claudin-18 splice variant 2
中文全称:密蛋白-18剪接变体2
种类:Homo sapiens
上市药物数量:1详情
临床药物数量:69详情
最高研发阶段:临床三期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定